Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul-Aug:(7-8):22-7.

[IMMUNOLOGICAL REACTIVITY AND CORRECTION OF IMMUNOLOGICAL DISORDERS BY BIOLOGICAL MEDICINES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS]

[Article in Ukrainian]
  • PMID: 26118077
Randomized Controlled Trial

[IMMUNOLOGICAL REACTIVITY AND CORRECTION OF IMMUNOLOGICAL DISORDERS BY BIOLOGICAL MEDICINES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS]

[Article in Ukrainian]
R I Il'nyts'kyĭ. Lik Sprava. 2014 Jul-Aug.

Abstract

The results of systemic immunological reactivity research were presented in 97 patients with chronic obstructive pulmonary disease (COPD) exacerbations. The patients were randomized on two groups. 67 patients, which additionally to standard anti-inflammatory therapy were prescribed different combinations of homotoxicological medicines, entered in a clinical group. The homotoxicological medicines such as Lymphomyosot, Galium-Heel®, Traumeel S, Echinacea compositum S, Bronchalis-Heel®, Mucosa compositum were prescribed according to the value of immune-regulatory index and type of T-cells immune disorders. 30 patients, which got standard anti-inflammatory therapy, entered in the group. of comparison. For the patients of clinical group immunological values were improved after the conducted treatment, unlike the patients of group of comparison in which an immunodeficiency was deepened.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources